{
    "clinical_study": {
        "@rank": "73687", 
        "arm_group": {
            "arm_group_label": "Ceftaroline fosamil", 
            "arm_group_type": "Experimental", 
            "description": "IV ceftaroline fosamil 600 mg infused over 60 (\u00b1 10) minutes every 12 hours (dosing may be adjusted for renal impairment)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and efficacy of ceftaroline fosamil in\n      elderly subjects with community-acquired bacterial pneumonia (CABP) receiving antibiotic\n      therapy in the hospital."
        }, 
        "brief_title": "Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Community-Acquired Bacterial Pneumonia (CABP)", 
        "condition_browse": {
            "mesh_term": [
                "Pneumonia, Bacterial", 
                "Pneumonia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter study of ceftaroline fosamil in elderly subjects (\u2265 65 years of age)\n      with CABP. Adjunctive macrolide therapy is to be used at the Investigator's discretion. A\n      switch to oral treatment may be allowed at the discretion of the Investigator. The total\n      duration of therapy is 5 to 7 days; a minimum of 48 hours of study drug is required."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female \u2265 65 years of age.\n\n          2. Presence of CABP warranting hospitalization.\n\n          3. Acute illness with \u2265 2 clinical signs or symptoms of lower respiratory tract\n             infection.\n\n          4. Radiographically confirmed pneumonia.\n\n        Exclusion Criteria:\n\n          1. History of any hypersensitivity or allergic reaction to any \u03b2-lactam or macrolide\n             antibacterial agent.\n\n          2. Confirmed or suspected respiratory tract infection due solely to an atypical\n             bacterial, mycobacterial, viral, or fungal pathogen.\n\n          3. More than 24 hours of potentially effective antibacterial therapy within 96 hours\n             prior to enrollment.\n\n          4. Life expectancy of < 30 days or presence of an order of Do Not Resuscitate (DNR).\n\n          5. Evidence of significant hematologic, hepatic, or immunologic impairment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666743", 
            "org_study_id": "CPT-MD-34"
        }, 
        "intervention": {
            "arm_group_label": "Ceftaroline fosamil", 
            "description": "IV ceftaroline fosamil 600 mg infused over 60 (\u00b1 10) minutes every 12 hours (dosing may be adjusted for renal impairment)", 
            "intervention_name": "Ceftaroline fosamil", 
            "intervention_type": "Drug", 
            "other_name": [
                "Teflaro\u00ae", 
                "PPI-0903", 
                "TAK-599", 
                "TAK599", 
                "PPI0903"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Community-Acquired Pneumonia", 
            "Lung", 
            "Adult", 
            "Infections"
        ], 
        "lastchanged_date": "February 7, 2013", 
        "link": {
            "description": "Sponsor Website", 
            "url": "http://www.cerexa.com"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Elderly Subjects With Community-Acquired Bacterial Pneumonia", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety evaluations will be conducted and assessments will include:\nAdverse events including deaths will be evaluated.\nLaboratory: complete blood count with differential, and chemistry panel.", 
            "measure": "Evaluate the safety of ceftaroline fosamil in elderly subjects (\u2265 65 years) with community-acquired bacterial pneumonia (CABP)", 
            "safety_issue": "Yes", 
            "time_frame": "Between 3 and 33-37 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666743"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Efficacy outcome measures:\nTime to clinical stability\nLength of stay\nClinical outcome at End-of-Intravenous Study Drug, End-of-Therapy, and Test-of-Cure\nMortality\n30-day readmission", 
            "measure": "Evaluate the efficacy of ceftaroline fosamil in elderly subjects (\u2265 65 years) with community-acquired bacterial pneumonia (CABP)", 
            "safety_issue": "No", 
            "time_frame": "30 days following discharge from the hospital, anticipated between 33 to 37 days."
        }, 
        "source": "Cerexa, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cerexa, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013", 
        "why_stopped": "Change in strategy."
    }
}